| JOURNAL HOME | CME HOME | THIS MONTH | PAST ISSUES | ETOC | COLLECTIONS |
| AUTHORS | REVIEWERS | EDITORIAL BOARD | FEEDBACK | RSS | HELP |
| ||||||||||||||
| ||||||||||||||
|
|
|
|
||||||||||||
|
||||||||||||||
*Innovex Inc., Lenexa, Kansas;
Clinical Research Center, New Orleans, Louisiana; and
Alliance Pharmaceutical Corp., San Diego, California
Address correspondence and reprint requests to Peter E. Keipert, PhD, Alliance Pharmaceutical Corp., 3040 Science Park Rd., San Diego, CA 92121.
Previous perfluorocarbon (PFC) emulsions have been associated with transient adverse events (i.e., platelet activation, decreased platelet count, febrile responses, changes in hemodynamic function). The Phase I studies described in this report were parallel, randomized, double-blinded, placebo-controlled studies conducted in 48 healthy volunteers (n = 24 per study) with perflubron emulsion (OxygentTM; Alliance Pharmaceutical Corp., San Diego, CA). Because of the decreased platelet counts observed with previous PFC emulsions and the intended use of perflubron emulsion in surgical patients, these studies assessed postdosing coagulation responses and hemostasis. PFC pharmacokinetic variables were also evaluated. The primary endpoint for examination of coagulation effects was prospectively defined as bleeding time. Subjects received either saline (3 mL/kg) control, or perflubron emulsion at 1.2 g PFC/kg or 1.8 g PFC/kg, and were evaluated for a 14-day period. No postinfusion changes in bleeding time or differences in ex vivo agonist-induced platelet aggregation were observed. A 17% reduction in platelet count was observed 3 days after dosing in the 1.8-g PFC/kg group; levels recovered to baseline by Day 7. The intravascular half-life of perflubron for the first 24 h was dose dependent: 9.4 ± 2.2 h and 6.1 ± 1.9 h in the 1.8- and 1.2-g PFC/kg groups, respectively. Results indicate that this perflubron emulsion did not affect coagulation function in healthy volunteers.
Implications: In major surgical procedures, perfluorocarbon-based temporary oxygen carriers are potentially important alternatives to blood transfusion. Newer, second-generation perfluorocarbon-based oxygen carriers have been developed to improve on the short-term side effects observed with earlier formulations. This report summarizes Phase I clinical safety data in healthy volunteers receiving the oxygen carrier, perflubron emulsion.
This article has been cited by other articles:
|
|
 |
|
  H. Dainer, J. Nelson, K. Brass, E. Montcalm-Smith, and R. Mahon Short oxygen prebreathing and intravenous perfluorocarbon emulsion reduces morbidity and mortality in a swine saturation model of decompression sickness J Appl Physiol, March 1, 2007; 102(3): 1099 - 1104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Yoshitani, F. de Lange, Q. Ma, H. P. Grocott, and G. B. Mackensen Reduction in Air Bubble Size Using Perfluorocarbons During Cardiopulmonary Bypass in the Rat Anesth. Analg., November 1, 2006; 103(5): 1089 - 1093. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Hill, H. P. Grocott, B. J. Leone, W. D. White, M. F. Newman, and Neurologic Outcome Research Group of the Duke Hear Cerebral Physiology of Cardiac Surgical Patients Treated with the Perfluorocarbon Emulsion, AF0144 Ann. Thorac. Surg., October 1, 2005; 80(4): 1401 - 1407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Noveck, E. J. Shannon, P. T. Leese, J. S. Shorr, K. E. Flaim, P. E. Keipert, and C. M. Woods Randomized Safety Studies of Intravenous Perflubron Emulsion. II. Effects on Immune Function in Healthy Volunteers Anesth. Analg., October 1, 2000; 91(4): 812 - 822. [Abstract] [Full Text] [PDF]
|
|
|
